Annual Accounts Receivable
$13.00 M
+$13.00 M+100.00%
December 31, 2022
Summary
- As of February 8, 2025, SPPI annual accounts receivable is $13.00 million, with the most recent change of +$13.00 million (+100.00%) on December 31, 2022.
- During the last 3 years, SPPI annual accounts receivable has risen by +$12.55 million (+2846.94%).
Performance
SPPI Accounts Receivable Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
High & Low
Earnings dates
Quarterly Accounts Receivable
$32.76 M
+$19.76 M+152.04%
March 31, 2023
Summary
- As of February 8, 2025, SPPI quarterly accounts receivable is $32.76 million, with the most recent change of +$19.76 million (+152.04%) on March 31, 2023.
Performance
SPPI Quarterly Accounts Receivable Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
High & Low
Earnings dates
Accounts Receivable Formula
Accounts Receivable = Total Credit Sales − Amount Collected from Credit Sales
SPPI Accounts Receivable Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | +100.0% | - |
| 3 y3 years | +2846.9% | +7429.9% |
| 5 y5 years | -59.7% | -1.9% |
SPPI Accounts Receivable Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | at high | -100.0% | at high | -100.0% |
| 5 y | 5-year | at high | -100.0% | at high | -100.0% |
| alltime | all time | -85.9% | -100.0% | -64.5% | -100.0% |
Spectrum Pharmaceuticals Accounts Receivable History
| Date | Annual | Quarterly |
|---|---|---|
| Mar 2023 | - | $32.76 M(+152.0%) |
| Dec 2022 | $13.00 M(>+9900.0%) | $13.00 M(>+9900.0%) |
| Dec 2021 | $0.00(-100.0%) | $0.00(0.0%) |
| Sep 2021 | - | $0.00(0.0%) |
| Jun 2021 | - | $0.00(-100.0%) |
| Mar 2021 | - | $64.00 K(-4.5%) |
| Dec 2020 | $67.00 K(-84.8%) | $67.00 K(-85.2%) |
| Sep 2020 | - | $453.00 K(+2.7%) |
| Jun 2020 | - | $441.00 K(+1.4%) |
| Mar 2020 | - | $435.00 K(-1.4%) |
| Dec 2019 | $441.00 K(-98.5%) | $441.00 K(-8.7%) |
| Sep 2019 | - | $483.00 K(-81.0%) |
| Jun 2019 | - | $2.54 M(-83.0%) |
| Mar 2019 | - | $14.94 M(-50.0%) |
| Dec 2018 | $29.87 M(-7.4%) | $29.87 M(+1.3%) |
| Sep 2018 | - | $29.48 M(+6.6%) |
| Jun 2018 | - | $27.66 M(-17.1%) |
| Mar 2018 | - | $33.38 M(+3.5%) |
| Dec 2017 | $32.26 M(-18.9%) | $32.26 M(-14.6%) |
| Sep 2017 | - | $37.77 M(-10.0%) |
| Jun 2017 | - | $41.98 M(+6.3%) |
| Mar 2017 | - | $39.49 M(-0.7%) |
| Dec 2016 | $39.78 M(+30.9%) | $39.78 M(-6.3%) |
| Sep 2016 | - | $42.47 M(+23.7%) |
| Jun 2016 | - | $34.32 M(+78.3%) |
| Mar 2016 | - | $19.25 M(-36.7%) |
| Dec 2015 | $30.38 M(-57.1%) | $30.38 M(-36.9%) |
| Sep 2015 | - | $48.15 M(+15.5%) |
| Jun 2015 | - | $41.68 M(-39.4%) |
| Mar 2015 | - | $68.75 M(-2.8%) |
| Dec 2014 | $70.76 M(+43.0%) | $70.76 M(+17.8%) |
| Sep 2014 | - | $60.09 M(+5.9%) |
| Jun 2014 | - | $56.74 M(+5.1%) |
| Mar 2014 | - | $54.01 M(+9.1%) |
| Dec 2013 | $49.48 M(-46.3%) | $49.48 M(-9.9%) |
| Sep 2013 | - | $54.92 M(+4.9%) |
| Jun 2013 | - | $52.38 M(+32.8%) |
| Mar 2013 | - | $39.43 M(-57.2%) |
| Date | Annual | Quarterly |
|---|---|---|
| Dec 2012 | $92.17 M(+78.3%) | $92.17 M(+1.3%) |
| Sep 2012 | - | $90.94 M(+7.2%) |
| Jun 2012 | - | $84.84 M(+53.2%) |
| Mar 2012 | - | $55.38 M(+7.1%) |
| Dec 2011 | $51.70 M(+145.6%) | $51.70 M(+8.2%) |
| Sep 2011 | - | $47.77 M(+2.8%) |
| Jun 2011 | - | $46.47 M(-10.6%) |
| Mar 2011 | - | $52.00 M(+147.0%) |
| Dec 2010 | $21.05 M(+143.1%) | $21.05 M(+122.4%) |
| Sep 2010 | - | $9.46 M(+10.8%) |
| Jun 2010 | - | $8.54 M(+36.5%) |
| Mar 2010 | - | $6.26 M(-27.7%) |
| Dec 2009 | $8.66 M(-11.4%) | $8.66 M(+95.0%) |
| Sep 2009 | - | $4.44 M(+190.1%) |
| Jun 2009 | - | $1.53 M(-75.7%) |
| Mar 2009 | - | $6.31 M(-35.5%) |
| Dec 2008 | $9.78 M(+5018.3%) | $9.78 M(+5155.9%) |
| Sep 2008 | - | $186.00 K(-50.9%) |
| Jun 2008 | - | $379.00 K(+351.2%) |
| Mar 2008 | - | $84.00 K(-56.0%) |
| Dec 2007 | $191.00 K(-83.4%) | $191.00 K(-85.8%) |
| Sep 2007 | - | $1.34 M(+1329.8%) |
| Jun 2007 | - | $94.00 K(-24.2%) |
| Mar 2007 | - | $124.00 K(-89.2%) |
| Dec 2006 | $1.15 M(+300.7%) | $1.15 M(-5.3%) |
| Sep 2006 | - | $1.21 M(+412.2%) |
| Jun 2006 | - | $237.00 K(0.0%) |
| Mar 2006 | - | $237.00 K(-17.4%) |
| Dec 2005 | $287.00 K(+44.2%) | $287.00 K(-18.9%) |
| Sep 2005 | - | $354.00 K(+47.5%) |
| Jun 2005 | - | $240.00 K(+20.6%) |
| Dec 2004 | $199.00 K(-2.5%) | $199.00 K(+4875.0%) |
| Mar 2004 | - | $4000.00(-99.8%) |
| Sep 2003 | - | $1.65 M(+711.2%) |
| Dec 2002 | $204.00 K(-57.0%) | $204.00 K(-57.0%) |
| Dec 2001 | $474.00 K(+41.9%) | $474.00 K(+41.9%) |
| Dec 2000 | $334.10 K(+125.7%) | $334.10 K(+125.7%) |
| Dec 1999 | $148.00 K(+48.0%) | $148.00 K(+48.0%) |
| Dec 1998 | $100.00 K | $100.00 K |
FAQ
- What is Spectrum Pharmaceuticals annual accounts receivable?
- What is the all time high annual accounts receivable for Spectrum Pharmaceuticals?
- What is Spectrum Pharmaceuticals annual accounts receivable year-on-year change?
- What is Spectrum Pharmaceuticals quarterly accounts receivable?
- What is the all time high quarterly accounts receivable for Spectrum Pharmaceuticals?
What is Spectrum Pharmaceuticals annual accounts receivable?
The current annual accounts receivable of SPPI is $13.00 M
What is the all time high annual accounts receivable for Spectrum Pharmaceuticals?
Spectrum Pharmaceuticals all-time high annual accounts receivable is $92.17 M
What is Spectrum Pharmaceuticals annual accounts receivable year-on-year change?
Over the past year, SPPI annual accounts receivable has changed by +$13.00 M (+100.00%)
What is Spectrum Pharmaceuticals quarterly accounts receivable?
The current quarterly accounts receivable of SPPI is $32.76 M
What is the all time high quarterly accounts receivable for Spectrum Pharmaceuticals?
Spectrum Pharmaceuticals all-time high quarterly accounts receivable is $92.17 M